医学
安慰剂
败血症
内科学
临床终点
机械通风
不利影响
临床试验
替代医学
病理
作者
Karl Werdan,Günter Pilz,Oskar Bujdoso,Peter Fraunberger,G. Neeser,Roland E. Schmieder,Burkhard Viell,W Marget,Margret Seewald,Peter Walger,R. Stuttmann,Norbert Speichermann,C. Peckelsen,Volkhard Kurowski,H.-H. Osterhues,Ljiljana Verner,R. O. Neumann,Ursula Müller‐Werdan
出处
期刊:Critical Care Medicine
[Ovid Technologies (Wolters Kluwer)]
日期:2007-12-01
卷期号:35 (12): 2693-2701
被引量:172
标识
DOI:10.1097/01.ccm.0000295426.37471.79
摘要
Intravenous immunoglobulin as an adjunctive treatment in sepsis was regarded as promising by a Cochrane meta-analysis of smaller trials. In this phase III multicenter trial, we assessed whether intravenous immunoglobulin G (ivIgG) reduced 28-day mortality and improved morbidity in patients with score-defined severe sepsis.Randomized, double-blind, placebo-controlled, multicenter trial.Twenty-three medical and surgical intensive care units in university centers and large teaching hospitals.Patients (n = 653) with score-defined sepsis (sepsis score 12-27) and score-defined sepsis-induced severity of disease (Acute Physiology and Chronic Health Evaluation II score 20-35).Patients were assigned to receive either placebo or ivIgG (day 0, 0.6 g/kg body weight; day 1, 0.3 g/kg body weight).The prospectively defined primary end point was death from any cause after 28 days. Prospectively defined secondary end points were 7-day all-cause mortality, short-term change in morbidity, and pulmonary function at day 4. Six hundred fifty-three patients from 23 active centers formed the intention-to-treat group, 624 patients the per-protocol group (placebo group, n = 303; ivIgG group, n = 321). The 28-day mortality rate was 37.3% in the placebo group and 39.3% in the ivIgG group and thus not significantly different (p = .6695). Seven-day mortality was not reduced, and 4-day pulmonary function was not improved. Drug-related adverse events were rare in both groups. Exploratory findings revealed a 3-day shortening of mechanical ventilation in the surviving patients and no effect of ivIgG on plasma levels of interleukin-6 and tumor necrosis factor receptors I and II.In patients with score-defined severe sepsis, ivIgG with a total dose of 0.9 g/kg body weight does not reduce mortality.
科研通智能强力驱动
Strongly Powered by AbleSci AI